Answers are grounded in this paper and cite their sources.
Background: Rotavirus (RV) is the leading cause of viral gastroenteritis in infants and young children, accounting for nearly 120,000 deaths annually worldwide. Currently licensed live-attenuated oral RV vaccines show reduced efficacy in low- and middle-income countries and high requirement for vaccine storage and transportation. Consequently, there is an urgent need to develop non-replicating RV vaccines. The VP8* protein of RV has been considered a promising antigen candidate for recombinant protein-based vaccines; however, its intrinsic immunogenicity remains suboptimal. This study aimed to enhance VP8* immunogenicity by conjugating it to the cholera toxin B subunit (CTB) using the SpyCatcher/SpyTag bioconjugation system. Methods: A conjugate protein vaccine, termed VP8::CTB, was generated by coupling SpyTag003-appended RV VP8* (VP8-ST) to SpyCatcher003-fused CTB (CTB-SC). The resulting VP8::CTB conjugate was characterized, and its immunogenicity was evaluated in mice by assessing antigen-specific antibody responses and RV-neutralizing activity. Furthermore, the protective efficacy of purified IgG from immunized mice was investigated by performing a passive protection assay in suckling mice. Results: VP8::CTB elicited significantly higher titers of RV-neutralizing antibodies than VP8-ST alone. Notably, purified IgG from VP8::CTB-immunized mice conferred complete protection against RV-induced diarrhea in suckling mice within the passive protection model. Conclusions: Our findings underscore that the VP8::CTB conjugate, through enhanced immunogenicity and protective efficacy, provides a promising candidate for the advancement of next-generation recombinant protein-based RV vaccines.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: